Point72 Hong Kong’s Alexion Pharmaceuticals ALXN Stock Holding History

Point72 Hong Kong’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-36,600	Closed	-$5.72M	–	2357
2020 Q4	$5.72M	Buy	+36,600	New	+$4.7M	0.26%	65

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Point72 Hong Kong's ALXN Position: Q3 2021 in Review

Point72 Hong Kong sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 480 shares — an estimated $88K sold.

Point72 Hong Kong first reported a position in ALXN in Q1 2015 and held it in 12 quarters. The position peaked at $1.08M in Q4 2020. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Point72 Hong Kong reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Point72 Hong Kong sold 480 Alexion Pharmaceuticals shares in Q3 2021, an estimated $88K.
Point72 Hong Kong first reported a position in Alexion Pharmaceuticals in Q1 2015 and held it in 12 quarters.
Point72 Hong Kong's Alexion Pharmaceuticals position peaked at $1.08M in Q4 2020.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Point72 Hong Kong's 13F filing for Q3 2021, filed 15 Nov 2021.